Mugnier Bénédicte, Daumas Aurélie, Couderc Anne-Laure, Mizzi Barbara, González Thomas, Amrani Anne, Lévêque Pierre, Aymes Brice, Argenson Jean-Nöel, Villani Patrick
APHM, Hôpital Sainte Marguerite, Service de Médecine Interne Gériatrie et Thérapeutique, Marseille, France.
APHM, Hôpital La Timone, Service de Médecine Interne Gériatrie et Thérapeutique, Marseille, France.
J Women Aging. 2019 Nov-Dec;31(6):553-565. doi: 10.1080/08952841.2018.1529473. Epub 2018 Oct 8.
The clinical efficacy of anti-osteoporotic treatments in old patients is discussed. The aim of this study was to assess if the use of anti-osteoporotic treatments for the secondary prevention of osteoporotic fractures could reduce the risk of refractures in patients over 75 years old in a Fracture Liaison Service. In this population of frail, elderly patients presenting with a recent osteoporotic fracture, we observed that the refracture incidence was similar in the treated group and the untreated group during the first year. However, 30 months after the index fracture, the osteoporosis medication for a year or more reduced the incidence of refractures by 70%.
讨论了抗骨质疏松治疗在老年患者中的临床疗效。本研究的目的是评估在骨折联络服务中,使用抗骨质疏松治疗进行骨质疏松性骨折的二级预防是否可以降低75岁以上患者再次骨折的风险。在这群近期发生骨质疏松性骨折的体弱老年患者中,我们观察到,在第一年,治疗组和未治疗组的再次骨折发生率相似。然而,在初次骨折30个月后,使用骨质疏松药物一年或更长时间可使再次骨折的发生率降低70%。